09 May, 2019
Summary of interim report - first quarter 2019: Successful development of a dry, temperature-stable formulation of Adenovirus resulted in a filed patent application and a significant milestone for Ziccum. Dialogue with potential Customers and partners continue with increased intensity, and an application has been submitted to Horizon 2020 step 2.
January - March 2019
Net sales SEK 0,0 (190)
Operating profit SEK -1,689 thousand (-137)
Earnings per share before and after dilution SEK -0.28 (-0.05)
Significant events during First Quarter 2019
- Ziccum reported on January 10, 2019 that the company had filed the patent application for Adenovirus with dry and temperature-stable formulation that meets WHO"s CTC status requirements. The dry formulation ("powder") generated by Ziccum"s technology in LaminarPace© is rapidly dissolved when adding sterile water after which vaccination or treatment can be performed.
- During the first quarter of 2019, we submitted our Phase 2 application for Horizon 2020
For further information please visit www.ziccum.com
For more information about Ziccum, please contact:
Göran Conradson: CEO Ziccum AB
Mob: +46 709 61 55 99
Ziccum AB (publ) develops new patented formulations of biological drugs where sensitivity to temperature differences, especially during transportation, currently limits medical and so commercial potential. The company’s patented technology, LaminarPace, develops dry powder formulations of drugs and vaccines that currently only exist in liquid form. By doing so Ziccum can increase the availability of drugs and vaccines in existing markets—and open up new ones.
The information above was provided by Ziccum AB (publ) through the above contact person, for publication on May 9, 2019.